Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Wako to Launch Coronavirus Test on April 15
April 6, 2020
- Sumitomo Dainippon, Ehime Univ. Aim to Make New Malaria Vaccine IND-Ready by March 2022
April 6, 2020
- Big 3 Generic Maker Curbing Valsartan Shipments amid India Lockdown
April 6, 2020
- Japan Generic Market Crosses 1 Trillion Yen Mark in 2019: Fuji Keizai
April 6, 2020
- Denka to Resume Production of Compound for Avigan
April 3, 2020
- Alfresa Allies with Cell Therapy Startup; Possible Tripartite Collaboration with Rohto
April 3, 2020
- Takeda Launches Dedicated COVID-19 Website to Inform of Product Supply, R&D Status
April 3, 2020
- Eisai, Seikagaku Pair Up for Osteoarthritis Drug in China
April 2, 2020
- Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline
April 2, 2020
- Pfizer Pausing Global Trial Recruitments, but Not in Japan
April 2, 2020
- Daiichi Sankyo Gets License to Ultragenyx’s Gene Therapy Manufacturing Techs
April 2, 2020
- Adcetris plus Chemo Gets EU Panel OK for Front-Line Use: Takeda
April 2, 2020
- Chugai Maps Out Digital Vision for 2030 Aiming at Value Chain Optimization, Novel Drug Discovery
April 2, 2020
- Takeda Introduces Claw-Back Policy for Executives Liable for Business Loss, Misconducts
April 2, 2020
- Post-Promotion Guidelines - 2: Takeda Evaluating “Non-Sales” Factors through Quality Conversations with Bosses
April 1, 2020
- Myovant Licenses European Rights for Relugolix Combo to Gedeon Richter
April 1, 2020
- SanBio Ties Up with China’s Ocumension for Stem Cell Therapies for Eyes
April 1, 2020
- Shionogi Files Xofluza for Post-Exposure Prophylaxis in Taiwan
April 1, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Astellas Suspends Launch of New Clinical Studies in Virus-Hit Countries
April 1, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…